NCT00711126View on ClinicalTrials.gov

A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 21, 2008

Primary Completion Date

December 17, 2008

Study Completion Date

December 17, 2008

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GW642444

2.5mcg IV

DRUG

GW642444

5mcg IV

DRUG

GW642444

10mcg IV

DRUG

GW642444

100mcg inhaled

DRUG

GW642444

20mcg IV

DRUG

GW642444

500mcg oral

Trial Locations (1)

NW10 7NS

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00711126 - A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By Injection | Biotech Hunter | Biotech Hunter